Skip to main content
main-content

Lymphoma

08-01-2018 | Lymphoma | News | Article

Anaplastic large-cell lymphoma risk with breast implants determined

Silicone-filled breast implants are associated with a high relative risk for developing anaplastic large-cell lymphoma in the breast, but the absolute risk remains low, confirms a population-based study.

Source:

JAMA Oncol 2018; Advance online publication

22-12-2017 | Lymphoma | News | Article

Editor's pick

CAR T-cell therapy effective for refractory large B-cell lymphomas

The results of two studies published in The New England Journal of Medicine support the use of autologous chimeric antigen receptor T cells directed against CD19 in patients with relapsed or refractory B-cell lymphomas.

Source:

N Engl J Med 2017; Advance online publication, ASH 2017; Atlanta, Georgia, USA

19-12-2017 | Lymphoma | News | Article

Acalabrutinib monotherapy promising for relapsed, refractory mantle cell lymphoma

Treatment with the second-generation Bruton tyrosine kinase inhibitor acalabrutinib induces durable responses in patients with relapsed or refractory mantle cell lymphoma, indicates the phase II ACE-LY-004 trial.

Source:

Lancet 2017; Advance online publication, ASH 2017; Atlanta, Georgia, USA

12-12-2017 | Lymphoma | News | Article

Brentuximab vedotin may improve outcome in advanced Hodgkin lymphoma

A treatment regimen incorporating the anti-CD30 antibody–drug conjugate brentuximab vedotin is more effective than standard therapy with doxorubicin, bleomycin, vinblastine, and dacarbazine when used as a frontline therapy in patients with advanced Hodgkin lymphoma, phase III trial data show.

Source:

N Engl J Med 2017; Advance online publication, ASH 2017; Atlanta, Georgia, USA

23-11-2017 | Oncology | News | Article

approvalsWatch

FDA announces approvals for sunitinib, obinutuzumab

More details on these decisions are a click away

06-11-2017 | Oncology | News | Article

approvalsWatch

Acalabrutinib receives FDA go-ahead for mantle cell lymphoma

Click through to read more on this accelerated approval

image credits